A COMPARISON OF METHODOLOGIES FOR ESTIMATING SURVIVAL IN PATIENTS TREATED WITH SECOND-GENERATION TYROSINE-KINASE INHIBITORS (TKIS) FOR CHRONIC MYELOID LEUKAEMIA (CML)

被引：0
|
作者：
Pennington, B. [1 ]
Batty, A. J. [1 ]
Clifton-Brown, E. [2 ]
机构：
[1] BresMed, Sheffield, S Yorkshire, England
[2] Pfizer Ltd, Tadworth, England
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.023
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A326 / A327
页数：2
相关论文
共 50 条
  • [31] Incidence and outcomes of chronic myeloid leukemia (CML) patients (pts) treated with second-generation tyrosine kinase inhibitors (TKI) who develop other chromosomal abnormalities (OCA).
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Burton, Elizabeth M.
    Dellasala, Sara
    Pierce, Sherry
    Kornblau, Steven Mitchell
    Verstovsek, Srdan
    O'Brien, Susan Mary
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)
    Abdelall, Waleed
    Kantarjian, Hagop M.
    Devendra, K. C.
    Akosile, Mary
    Borthakur, Gautam
    Verstovsek, Srdan
    Daver, Naval
    Pemmaraju, Naveen
    Naqvi, Kiran
    Garcia-Manero, Guillermo
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Ravandi, Farhad
    Konopleva, Marina
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [33] Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety
    Lagana, Alessandro
    Scalzulli, Emilia
    Bisegna, Maria Laura
    Carmosino, Ida
    Ielo, Claudia
    Costa, Alessandro
    Torrieri, Lorenzo
    Totaro, Matteo
    Martelli, Maurizio
    Breccia, Massimo
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (08) : 969 - 979
  • [34] Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML
    Ono, Takaaki
    Takahashi, Naoto
    Kizaki, Masahiro
    Kawaguchi, Tatsuya
    Suzuki, Ritsuro
    Yamamoto, Kazuhito
    Ohnishi, Kazunori
    Naoe, Tomoki
    Matsumura, Itaru
    CANCER SCIENCE, 2023, 114 (03) : 995 - 1006
  • [35] Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors
    Maeda, Yasuhiro
    Okamoto, Atsushi
    Kawaguchi, Shin-ichiro
    Konishi, Akiko
    Yamamoto, Kenta
    Eguchi, Go
    Kanai, Yoshitaka
    Yamaguchi, Terufumi
    ACTA HAEMATOLOGICA, 2017, 138 (03) : 140 - 142
  • [36] Echocardiographic Findings in Patients (pts) Receiving Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Chronic Myeloid Leukemia (CML)
    Gurguis, Christopher
    de Armas, Lizette Rodriguez
    Kantarjian, Hagop M.
    Boddu, Prajwal C.
    Jain, Preetesh
    Borthakur, Gautam
    Giza, Dana Elena
    Iliescu, Gloria
    Lopez-Mattei, Juan
    Kim, Peter
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Wierda, William G.
    Kornblau, Steven
    Jabbour, Elias J.
    Iliescu, Cezar
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [37] Adverse outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors - Reply
    Leong, Darryl
    Hillis, Christopher
    Aghel, Nazanin
    Pond, Gregory
    Seow, Hsien
    HEART, 2021, 107 (20) : 1680 - 1681
  • [38] Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors
    Casavecchia, Grazia
    Spinosa, Giuseppina
    De Gennaro, Luisa
    Zicchino, Stefano
    Gravina, Matteo
    Magnesa, Michele
    Di Biase, Matteo
    Brunetti, Natale Daniele
    ACTA CARDIOLOGICA, 2022, 77 (02) : 130 - 135
  • [39] IMPACT OF TYROSINE KINASE INHIBITORS (TKIS) ON THE FERTILITY OF CHRONIC MYELOID LEUKEMIA PATIENTS (CML) IN A SINGLE CENTER IN ALGERIA
    Yamina, B.
    Souad, T.
    Tayeb, A. Mohand
    HAEMATOLOGICA, 2015, 100 : 690 - 691
  • [40] Second-Generation Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Tefferi, Ayalew
    CANCER, 2011, 117 (02) : 234 - 237
12345